Disney surges, Uber stumbles, and AMD gains as US stocks edge higher today. Traders focus on Fed policy signals and sector ...

Shares of Sarepta Therapeutics cratered on Wednesday after the biopharmaceutical company trimmed its full-year forecast for ...

Sarepta stock plummeted Wednesday on a "double whammy" that includes its trimmed 2025 sales outlook and a critical FDA ...

Stock indexes today are trading higher on an easing of US-China trade tensions as representatives from both countries will meet for their first trade talks since President Trump imposed tariffs on US ...

Mary Jenkins; Associate Director, Investor Relation; Sarepta Therapeutics Inc. Douglas Ingram; President, Chief Executive Officer, Director; Sarepta Therapeutics Inc ...

Sarepta Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst consensus estimate of losses of ...

Stock futures rose on Wednesday on optimism around trade talks with China. Treasury Secretary Scott Bessent and Trade Representative Jamieson Greer are slated to meet with Chinese officials for the ...

SRPT reports mixed first-quarter 2025 results. The stock plunges after the company significantly lowers its 2025 sales guidance.

Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst consensus estimate of losses of 95 cents.

Sarepta has submitted a request to the FDA to include the death case in Elevidys’ label, and the agency plans to review the ...

Marvell (NASDAQ: MRVL) stock dropped 7% after the semiconductor announced it would postpone its Investor Day, initially ...

Sarepta’s stock dropped by 26% after the FDA named a vocal critic of its gene therapy programme to lead its biologics ...